A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: intensification (1), strengthening (84), augmentation (4), extension (76), increase (1000), further explanation (77)

MPF9 Solid tumour request form v10

Description
Lab use: Barcode Date: Specimen(s) received: Cellular Pathology UKAS reference: 8178 WGLS Southampton UKAS reference: 9194 Solid Tumour Te
Url
/Media/UHS-website-2019/Docs/Health-professionals/Pathology/MPF9-Solid-tumour-request-form.docx

Using your smartphone to help you hear - patient information

Description
If you have a long-term hearing loss, hearing aids are the best option to help improve your hearing. If you
Url
/Media/UHS-website-2019/Patientinformation/Audiology/Using-your-smartphone-to-help-you-hear-3450-PIL.pdf

Enhertu (trastuzumab deruxtecan)

Description
Chemotherapy Protocol BREAST CANCER ENHERTU (trastuzumab deruxtecan) ENHERTU is NOT the same drug as Kadcyla (trastuzumab emtansine) or generic trast
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Enhertu-trastuzumab-deruxtecan.pdf

Capecitabine-TrastuzumabIV-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine–Trastuzumab (IV)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (IV)-Tucatinib
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-IV-Tucatinib.pdf

Capecitabine-Trastuzumab-SC-Tucatinib

Description
Chemotherapy Protocol BREAST CANCER Capecitabine– Trastuzumab (SC)-Tucatinib Regimen • Breast Cancer – Capecitabine–Trastuzumab (SC)-Tucatinib
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine-Trastuzumab-SC-Tucatinib.pdf

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf
1 to 6 of 6